AAN

AAN 2025: Lecanemab shows sustained benefits in early Alzheimer's disease

April 8, 2025

Continuous treatment with lecanemab, an amyloid-beta antibody, led to sustained cognitive benefits and biomarker improvement in early Alzheimer’s disease (AD), according to findings presented at the American Academy of Neurology (AAN) annual meeting.

Study details: The Clarity AD open-label extension study evaluated the long-term safety and efficacy of lecanemab, in early symptomatic AD. The study includes 1,385 participants, assessing clinical and biomarker outcomes over 36 months, comparing early start and delayed start cohorts.

Results: Participants treated with lecanemab showed sustained benefits across clinical endpoints through 24 months. The separation between early and delayed start cohorts was maintained up to 36 months (p<0.05). Biomarker improvements were observed as early as 3 months in newly-treated participants. Consistent rates of clinical stability or improvements were noted, with the highest rates in the low tau group at 36 months (no decline: 59%; improvement: 51%). No new safety signals were detected, and amyloid-related imaging abnormality rates remained low.

Sources:

Irizarry, M et al. The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer’s Disease. P1: Aging, Dementia, and Behavioral Neurology: Alzheimer’s Disease Diagnostics and Biomarkers 1. AAN 2025. https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-004158.html

(2025, March 25). Eisai Inc. Eisai to present lecanemab real-world experience data and findings from neurology portfolio at the American Academy of Neurology (AAN) annual meeting. [Press release]. https://media-us.eisai.com/2025-03-25-EISAI-TO-PRESENT-LECANEMAB-REAL-WORLD-EXPERIENCE-DATA-AND-FINDINGS-FROM-NEUROLOGY-PORTFOLIO-AT-THE-AMERICAN-ACADEMY-OF-NEUROLOGY-AAN-ANNUAL-MEETING